IgA nephropathy: open trials in Russia

• NCT04557462

  A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

  Trial Treatment · Phase 3 · Novartis Pharmaceuticals

  Rostov-on-Don · Saint Petersburg

  Registry updated 2026-10-05

• NCT07074951

  Tonsillectomy and Immunosuppression in Caucasian Patients With High-risk IgA-nephropathy

  Trial Treatment · St. Petersburg State Pavlov Medical University

  Research Institute of Nephrology (Pavlov Medical University), Saint Petersburg · St. Petersburg State Pavlov Medical University, Saint Petersburg

  Registry updated 2025-07-20

• NCT07056595

  Finerenone in Patients With IgA-nephropathy: Prospective Interventional Trial

  Trial Treatment · Botkin Hospital

  Botkin Hospital, Moscow

  Registry updated 2025-07-09

All IgA nephropathy trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error